QT Prolongation and Oncology Drug Development

Cardiac Electrophysiology Clinics

Volumn 7, Issue 2, 2015, Pages 341-355

  Fradley, Michael G ^a   Moslehi, Javid ^b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer treatment; Cardio oncology; Cardiotoxicity; Chemotherapy; QT prolongation; Torsades de pointes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CISAPRIDE; CYTOTOXIC AGENT; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GREPAFLOXACIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MOXIFLOXACIN; NILOTINIB; PANOBINOSTAT; PONATINIB; POTASSIUM; PROTEIN TYROSINE KINASE INHIBITOR; QUINIDINE; RAZOXANE; ROMIDEPSIN; SODIUM; SUNITINIB; TAMOXIFEN; TERFENADINE; UNINDEXED DRUG; VANDETANIB; VORINOSTAT; CARDIOTOXIN;

AGING; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CUTANEOUS T CELL LYMPHOMA; DRUG FATALITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; FAINTNESS; GASTROINTESTINAL STROMAL TUMOR; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOTHERMIA; KIDNEY METASTASIS; MALIGNANT NEOPLASTIC DISEASE; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMORPHIC VENTRICULAR TACHYCARDIA; POTASSIUM CURRENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT INTERVAL; QT PROLONGATION; REVIEW; SODIUM CURRENT; SUDDEN CARDIAC DEATH; T CELL LYMPHOMA; THYROID MEDULLARY CARCINOMA; TORSADE DES POINTES; LONG QT SYNDROME;

ANTINEOPLASTIC AGENTS; CARDIOTOXINS; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 84930276825     PISSN: 18779182     EISSN: 18779190     Source Type: Journal    
DOI: 10.1016/j.ccep.2015.03.013     Document Type: Review

References (118)

1. Goldberger A.L. Clinical electrocardiography 2006, C.V. Mosby Co, Philadelphia. 7th edition.
2. Grant A.O. Cardiac ion channels. Circ Arrhythm Electrophysiol 2009, 2(2):185-194.
3. Al-Khatib S.M., LaPointe N.M., Kramer J.M., et al. What clinicians should know about the QT interval. JAMA 2003, 289(16):2120-2127.
4. Curigliano G., Spitaleri G., Fingert H.J., et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 2008, 44(4):494-500.
5. Jervell A., Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957, 54(1):59-68.
6. Ward O.C. Anew familial cardiac syndrome in children. JIr Med Assoc 1964, 54:103-106.
7. Zipes D.P. Mechanisms of clinical arrhythmias. JCardiovasc Electrophysiol 2003, 14(8):902-912.
8. Gupta A., Lawrence A.T., Krishnan K., et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007, 153(6):891-899.
9. Roden D.M. Drug-induced prolongation of the QTinterval. NEngl J Med 2004, 350(10):1013-1022.
10. Roden D.M., Hoffman B.F. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 1985, 56(6):857-867.
11. Sicouri S., Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells (M cells) in the canine heart: quinidine and digitalis. JCardiovasc Electrophysiol 1993, 4(1):48-58.
12. Viskin S., Rosovski U., Sands A.J., et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005, 2(6):569-574.
13. Anttonen O., Junttila M.J., Rissanen H., et al. Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. Circulation 2007, 116(7):714-720.
14. Rautaharju P.M., Surawicz B., Gettes L.S., et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009, 119(10):e241-e250.
15. Postema P.G., De Jong J.S., Van der Bilt I.A., et al. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm 2008, 5(7):1015-1018.
16. Anderson M.E., Al-Khatib S.M., Roden D.M., et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002, 144(5):769-781.
17. Rautaharju P.M., Zhang Z.M., Prineas R., et al. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 2004, 93(8):1017-1021.
18. Milne J.R., Ward D.E., Spurrell R.A., et al. The ventricular paced QT interval-the effects of rate and exercise. Pacing Clin Electrophysiol 1982, 5(3):352-358.
19. Curigliano G., Spitaleri G., de Braud F., et al. QTc prolongation assessment in anticancer drug development: clinical and methodological issues. Ecancermedicalscience 2009, 3:130.
20. Heist E.K., Ruskin J.N. Drug-induced arrhythmia. Circulation 2010, 122(14):1426-1435.
21. Roden D.M. Clinical practice. Long-QT syndrome. NEngl J Med 2008, 358(2):169-176.
22. Rautaharju P.M., Zhou S.H., Wong S., et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992, 8(7):690-695.
23. Sides G.D. QT interval prolongation as a biomarker for torsades de pointes and sudden death in drug development. Dis Markers 2002, 18(2):57-62.
24. Zhang Y., Ouyang P., Post W.S., et al. Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2011, 174(4):403-411.
25. van Noord C., Dorr M., Sturkenboom M.C., et al. The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol 2010, 25(1):21-28.
26. Cheng J. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human. Fundam Clin Pharmacol 2006, 20(1):1-8.
27. Wu Z.Y., Yu D.J., Soong T.W., et al. Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis. JBiol Chem 2011, 286(25):22186-22194.
28. Gaborit N., Varro A., Le Bouter S., et al. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. JMol Cell Cardiol 2010, 49(4):639-646.
29. Antzelevitch C., Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002, 17(1):43-51.
30. Bednar M.M., Harrigan E.P., Ruskin J.N. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002, 89(11):1316-1319.
31. Makkar R.R., Fromm B.S., Steinman R.T., et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993, 270(21):2590-2597.
32. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long-QT syndrome. NEngl J Med 2003, 348(19):1866-1874.
33. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). JAm Coll Cardiol 2006, 48(5):e247-e346.
34. Choy A.M., Lang C.C., Chomsky D.M., et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997, 96(7):2149-2154.
35. McBride B.F., Min B., Kluger J., et al. An evaluation ofthe impact of oral magnesium lactate on thecorrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Ann Noninvasive Electrocardiol 2006, 11(2):163-169.
36. Selzer A., Wray H.W. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964, 30:17-26.
37. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci. Arch Mal Coeur Vaiss 1966, 59(2):263-272. [in French].
38. Lehmann M.H., Hardy S., Archibald D., et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996, 94(10):2535-2541.
39. Singh S., Zoble R.G., Yellen L., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000, 102(19):2385-2390.
40. Honig P.K., Woosley R.L., Zamani K., et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992, 52(3):231-238.
41. Monahan B.P., Ferguson C.L., Killeavy E.S., et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990, 264(21):2788-2790.
42. Flockhart D.A. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?. JClin Psychopharmacol 1996, 16(2):101-103.
43. Mandell L., Tillotson G. Safety of fluoroquinolones: an update. Can J Infect Dis 2002, 13(1):54-61.
44. Wysowski D.K., Bacsanyi J. Cisapride and fatal arrhythmia. NEngl J Med 1996, 335(4):290-291.
45. Richter J.E. Cisapride: limited access and alternatives. Cleve Clin J Med 2000, 67(7):471-472.
46. European Agency for the Evaluation of Medicinal Products (EMEA). ICH topic S7B: note for guidance on the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. (CPMP/ICH/423/02). 2005.
47. Dethlefsen C., Hojfeldt G., Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 2013, 138(3):657-664.
48. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. Br J Pharmacol 2008, 154(7):1382-1399.
49. Gintant G.A., Limberis J.T., McDermott J.S., et al. The canine Purkinje fiber: an invitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. JCardiovasc Pharmacol 2001, 37(5):607-618.
50. Lu Z., Wu C.Y., Jiang Y.P., et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med 2012, 4(131):131ra150.
51. Yang T., Chun Y.W., Stroud D.M., et al. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 2014, 130(3):224-234.
52. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2005, 2(2 Suppl):S9-S15.
53. Belardinelli L., Shryock J.C., Wu L., et al. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm 2005, 2(2 Suppl):S16-S22.
54. Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 2010, 159(1):49-57.
55. Bloomfield D.M., Kost J.T., Ghosh K., et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008, 84(4):475-480.
56. Committee for Medicinal Products for Human Use ICH topic E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs questions and answers (EMA/CHMP/ICH/310133/2008) 2012, EMEA, London, Available at:, Accessed August 27, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002878.pdf.
57. Shah R.R., Morganroth J. ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies. Br J Clin Pharmacol 2013, 75(4):959-965.
58. Locatelli M., Criscitiello C., Esposito A., et al. QT prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. Target Oncol 2015, 10(1):27-43.
59. Varterasian M., Meyer M., Fingert H., et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. JClin Oncol 2003, 21(17):3378-3379.
60. Piekarz R.L., Frye A.R., Wright J.J., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12(12):3762-3773.
61. US Department of Health and Human Services: common terminology criteria for adverse events (CTCAE), version 4.0, DHHS, NIH, NCI. 2009. Available at: Accessed March 9, 2015. http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference:8.5x11.pdf.
62. Fingert H., Varterasian M. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management. AAPS J 2006, 8(1):E89-E94.
63. Varterasian M., Fingert H., Agin M., et al. Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer. Clin Cancer Res 2004, 10(17):5967-5968. [author reply: 5968-9].
64. Naing A., Veasey-Rodrigues H., Hong D.S., et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 2012, 23(11):2960-2963.
65. Kim P.Y., Ewer M.S. Chemotherapy and QT prolongation: overview with clinical perspective. Curr Treat Options Cardiovasc Med 2014, 16(5):303.
66. Rust D.M., Soignet S.L. Risk/benefit profile of arsenic trioxide. Oncologist 2001, 6(Suppl 2):29-32.
67. Castaigne S., Chomienne C., Daniel M.T., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76(9):1704-1709.
68. Frankel S.R., Eardley A., Heller G., et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994, 120(4):278-286.
69. Hu J., Shen Z.X., Sun G.L., et al. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol 1999, 70(4):248-260.
70. Stone R.M., Mayer R.J. The unique aspects of acute promyelocytic leukemia. JClin Oncol 1990, 8(11):1913-1921.
71. Warrell R.P., Maslak P., Eardley A., et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994, 8(6):929-933.
72. Shen Z.X., Chen G.Q., Ni J.H., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89(9):3354-3360.
73. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. JClin Oncol 2001, 19(18):3852-3860.
74. Soignet S.L., Maslak P., Wang Z.G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. NEngl J Med 1998, 339(19):1341-1348.
75. Weinberg S.L. The electrocardiogram in acute arsenic poisoning. Am Heart J 1960, 60:971-975.
76. Niu C., Yan H., Yu T., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94(10):3315-3324.
77. Unnikrishnan D., Dutcher J.P., Varshneya N., et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001, 97(5):1514-1516.
78. Ohnishi K., Yoshida H., Shigeno K., et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000, 133(11):881-885.
79. Barbey J.T., Pezzullo J.C., Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. JClin Oncol 2003, 21(19):3609-3615.
80. Roboz G.J., Ritchie E.K., Carlin R.F., et al. Prevalence, management, and clinical consequences of qt interval prolongation during treatment with arsenic trioxide. JClin Oncol 2014, 32(33):3723-3728.
81. Barbey J.T. Cardiac toxicity of arsenic trioxide. Blood 2001, 98(5):1632. [author reply: 1633-4].
82. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. NEngl J Med 2005, 353(2):172-187.
83. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118(1):84-95.
84. Shah R.R., Morganroth J., Shah D.R. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013, 36(5):295-316.
85. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEngl J Med 2001, 344(14):1031-1037.
86. Ky B., Vejpongsa P., Yeh E.T., et al. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013, 113(6):754-764.
87. Bair S.M., Choueiri T.K., Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med 2013, 23(4):104-113.
88. Groarke J.D., Cheng S., Moslehi J. Cancer-drug discovery and cardiovascular surveillance. NEngl J Med 2013, 369(19):1779-1781.
89. Tefferi A., Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011, 86(7):610-611.
90. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. NEngl J Med 2006, 354(24):2542-2551.
91. Morgan T.K., Sullivan M.E. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog Med Chem 1992, 29:65-108.
92. Product monograph: sutent, sunitimib malate capsules 2006, Submission control no 102788, Pfizer Canada Inc, Kirkland (WA); Quebec (Canada).
93. Strevel E.L., Ing D.J., Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. JClin Oncol 2007, 25(22):3362-3371.
94. Miller K.D., Trigo J.M., Wheeler C., et al. Amulticenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005, 11(9):3369-3376.
95. Holden S.N., Eckhardt S.G., Basser R., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16(8):1391-1397.
96. Tamura T., Minami H., Yamada Y., et al. Aphase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. JThorac Oncol 2006, 1(9):1002-1009.
97. Heymach J.V., Johnson B.E., Prager D., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. JClin Oncol 2007, 25(27):4270-4277.
98. Kiura K., Nakagawa K., Shinkai T., et al. Arandomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. JThorac Oncol 2008, 3(4):386-393.
99. Kovacs M.J., Reece D.E., Marcellus D., et al. Aphase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145. Invest New Drugs 2006, 24(6):529-535.
100. Wells S.A., Gosnell J.E., Gagel R.F., et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. JClin Oncol 2010, 28(5):767-772.
101. Natale R.B., Thongprasert S., Greco F.A., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. JClin Oncol 2011, 29(8):1059-1066.
102. Zang J., Wu S., Tang L., et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 2012, 7(2):e30353.
103. Tam C.S., Kantarjian H., Garcia-Manero G., et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008, 112(3):516-518.
104. US Food and Drug Administration. Safety information: tasigna (nilotinib) capsule. 2014. Available at: Accessed November 17, 2014. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm218929.htm.
105. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1(4):287-299.
106. Shultz M.D., Cao X., Chen C.H., et al. Optimization of the invitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. JMed Chem 2011, 54(13):4752-4772.
107. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. JClin Oncol 2007, 25(21):3109-3115.
108. Lynch D.R., Washam J.B., Newby L.K. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Cardiol J 2012, 19(4):434-438.
109. Galetta F., Franzoni F., Cervetti G., et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005, 59(10):541-544.
110. Nousiainen T., Vanninen E., Rantala A., et al. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. JIntern Med 1999, 245(4):359-364.
111. Liu X.K., Katchman A., Ebert S.N., et al. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. JPharmacol Exp Ther 1998, 287(3):877-883.
112. Dowlati A., Robertson K., Cooney M., et al. Aphase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62(12):3408-3416.
113. Britten C.D., Rowinsky E.K., Soignet S., et al. Aphase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 2001, 7(12):3894-3903.
114. Hahn S.M., Bernhard E.J., Regine W., et al. APhase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 2002, 8(5):1065-1072.
115. Martin N.E., Brunner T.B., Kiel K.D., et al. Aphase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 2004, 10(16):5447-5454.
116. Robertson M.J., Kahl B.S., Vose J.M., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. JClin Oncol 2007, 25(13):1741-1746.
117. Carducci M.A., Musib L., Kies M.S., et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. JClin Oncol 2006, 24(25):4092-4099.
118. Camm A.J., Malik M., Yap Y.G. Acquired long QT syndrome 2004, Wiley-Blackwell, New York.